Lung Cancer

Article	Citations
Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis	146
Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study	125
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer	92
3 The Availability of Molecular Profiling Results at New Patient Review in NSCLC and the Impact on Patient Care	80
105 Implementation of a Lung Cancer Nurse Specialist 2WW Remote Outpatient Triage Clinic – Optimising Patient Access and Assessment	79
66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022–2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre	59
74 Is Age A Thing? Accessing Treatment for Pleural Mesothelioma	54
2 The role of cellular pathology departments in the improvement of turnaround times for lung adenocarcinoma biomarker testing	52
64 Variability in patient pathways and experiences of care in peritoneal mesothelioma	52
116 Health and Wellbeing days for Lung Cancer patients	50
133 Review of Advanced Lung cancer treatment in relation to the NLCA report	48
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England	48
119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study	46
164 Participant recollection of recent imaging is unreliable for determining eligibility for lung cancer screening	45
216 Prolonged Localised Inflammatory Response following Bronchoscopic Thermal Vapour Ablation Therapy mimicking Lung Cancer	43
171 The impact of introducing a Targeted Lung Health Check on oncology services at Portsmouth Hospitals University NHS Trust	43
206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib	42
149 Stereotactic radiosurgery (SRS) for the treatment of brain metastases: Outcomes for lung cancer patients in South Wales	41
36 Summary of data for CT-guided percutaneous lung biopsy from West Yorkshire and Harrogate Cancer Alliance in 2021	40
213 Selpercatinib in RET Fusion Lung Adenocarcinoma	40
219 Oesophageal EUS-guided Pericardiocentesis: A Therapeutic Conundrum in Patient with EGFR-positive Metastatic Lung Adenocarcinoma and Posterior Pericardial Tamponade	40
90 Real world Time on Treatment (rwToT) of Pembrolizumab in Stage IV NSCLC—a single centre experience	39
48 Real world outcomes of a lung cancer genomic tumour advisory board: a single-centre experience in the United Kingdom	39
217 Atypical pseudoprogression in non-small cell lung cancer treated with pembrolizumab.	38
84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer	37

93 Evaluating real-world tepotinib-related toxicity data across five UK cancer units- A case-series	37
87 Overview of patients who complete two years of chemotherapy-immunotherapy for metastatic non-small cell lung cancer in Leicester	36
153 Lattice radiotherapy (LRT): Safely Dose Escalating Palliative Radiotherapy	36
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients	35
130 A review of patients diagnosed with non-small cell lung cancer, stage I-II disease and a performance status of 0–1 over the past 10 years	35
111 Patient, professional and carer experiences of communicating a lung cancer diagnosis: A systematic review of qualitative evidence	35
136 Supporting the wellbeing of oncodriven lung cancer patients online: a qualitative study	35
143 Using ProKnow to explore the incidence of radiation pneumonitis in relation to GTV size in Stage III Non-Small Cell Lung Cancer (NSCLC) concurrent Chemoradiotherapy (cCRT) patients and its impact	34
205 An update on the VIGILANCE study: Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer	34
196 Studying the Characteristics and Outcomes of People with Lung Cancer to Implement a Prehabilitation Service Pathway–A Retrospective Study	32
178 Utility of PET-CT for nodule discrimination in the SUMMIT Study	32
207 Exploring the experiences of rural and coastal people with lung cancer and their informal carers' in accessing and engaging in treatment: A qualitative interview study	31
198 Early experience with neoadjuvant immunochemotherapy and it's safety and efficacy	30
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy	30
Evaluating the safety of antibody-drug conjugates in lung cancer: A systematic review and meta-analysis	30
181 Targeted Lung Health Check screening outcomes from invited ‘aged-in’ populations	30
Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study	29
Evaluation of teleguided high-intensity exercise rehabilitation at home before lung-cancer surgery (PREPACHIR Study)	29
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy	28
Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance	28
Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients	28
Comparison of molecular subtype composition between independent sets of primary and brain metastatic small cell lung carcinoma and matched samples	27
Defining the needle in a haystack: A compendium of genomic, pathologic, and clinical characteristics of rare pulmonary tumors	27
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications	27
Genomic analysis of comprehensive next generation sequencing data to explore the criteria for MET amplification as an actionable biomarker in NSCLC	27
Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study	27
The Scottish Mesothelioma Network: impact of a national multidisciplinary team on overall survival in malignant pleural mesothelioma	26
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy	26
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis	25
Correlation of 18F-FDG-PET/CT metabolic parameters with PD-L1 tumour proportion score (TPS) in resected non-small cell lung cancer (NSCLC)	25
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer	25
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial	25
Adapting lung cancer diagnostics during the Covid-19 pandemic	25
Advances in the treatment of RET-fusion-positive lung cancer	25
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)	25
The effects of the COVID-19 pandemic on the lung cancer service at Northwick Park Hospital (NWPH)	24
Evaluation of telephone consultations for follow up lung cancer patients at Royal Papworth Hospital, undertaken instead of face-to-face consultations during the Covid-19 pandemic	24
Impact of COVID-19 on mesothelioma clinical nurse specialists	24
Community Access To Chest CT (CATCH): experiences from a tertiary centre of the CATCH CT protocol for equivocal chest radiographs requested in primary care	23
Where the nose is going to help the eye: Sniffing lung cancer	23
The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report	23
Contents	22
Preliminary review of the Lung One Stop Clinic in Greater Manchester	22
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting	22
Improving patient selection and referral for CT-guided lung biopsy at a tertiary referral centre	21
An evaluation of a new local anaesthetic thoracoscopy service in Edinburgh	21
Radicality of lymphadenectomy in lung cancer resections by thoracotomy and video-assisted thoracoscopic approach: A prospective, multicentre and propensity-score adjusted study	21
Increased proportion of patients diagnosed with lung cancer as a result of an acute hospital admission during the COVID-19 pandemic, and associated inequalities	21
Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia	21
The role of mediastinoscopy following EBUS	21

Editorial Board	20
Efficacy and safety of durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer: a single institution experience at University Hospital of North Midlands (UHNM) in the United Kingdom	20
Implementation of an antihypertensive deprescribing protocol in frail, stage IV lung cancer patients in clinical practice	20
Preoperative PET-SUVmax and volume based PET parameters of the primary tumor fail to predict nodal upstaging in early-stage lung cancer	20
Development and delivery of a second SABR service in Wales	20
Reducing inequalities in lung cancer: a new self-referral chest x-ray (SRCXR) service for symptoms that could be caused by lung cancer in Greater Manchester	20
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent	20
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study	20
The spectrum of MET exon 14 skipping alterations in a UK population	20
A retrospective evaluation of risk factors for and incidence of Pneumocystis jirovecii pneumonia (PJP) in Patients treated with continuous hyperfractionated accelerated radiotherapy (CHART) in the Wes	19
Dynamic monitoring of lung immune prognostic index (LIPI) in thoracic tumours treated with immune checkpoint inhibitors	19
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial	19
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma	19
Does pleurodesis leave patients at risk from malignant ascites or contralateral pleural effusions: a prevalence study?	19
Radical chemoradiation for stage III NSCLC patients with N3 disease: futile exercise or a fruitful venture?	19
30-day mortality after SACT (systemic anti-cancer therapy) for lung cancer at the Northern Trust SACT clinic (2019-2021)	19
Evaluating the need for, and provision of, a dietetic service in patients with early-stage lung cancer	19
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study	18
A retrospective study of pneumonectomy lung cancer patients spanning a 20 year period	18
Impact of prehabilitation on pre-operative function, post-operative complications and length of stay in resectable lung cancers	18
Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC	18
The impact of reminder invitations on participation in community-based lung cancer screening	18
Embedding qualitative research in lung cancer trials: Thoracic Umbrella Radiotherapy Study in stage IV NSCLC: TOURIST	18
Contents	18
Indwelling pleural catheter infections: a cautionary tale	18
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes	18
The impact of virtual lung MDT meetings (MDTMs) in response to the COVID-19 pandemic	17
Routine CT scans across the UK	17
Pulmonary anatomy, pathology and treatment: What will be the artificial intelligence and deep-learning role on them?	17
Use of systemic anti-cancer treatments in advanced stage non-small cell lung cancer during the SARS-CoV-2 pandemic in England and Wales: an analysis of the Rapid Cancer Registration Dataset	17
The added value of screening for nutritional impact symptoms at the time of the new patient respiratory clinic for patients with suspected lung cancer	17
A case study of an incidental finding of PJP on CBCT imaging in a stage III lung patient undergoing radical radiotherapy: a therapeutic radiographers experience	17
Use of DOACS for cancer-associated VTE in Great Western Hospital	17
‘Do It For Yourself’: raising awareness of lung cancer symptoms to support early diagnosis	17
Discordance between pre-operative and post-operative cell type after pleurectomy/decortication for malignant pleural mesothelioma: a possible detrimental effect of induction chemotherapy	17
Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases	17
Non-metastatic small cell lung cancer: real-world data for patients receiving radical concurrent chemoradiotherapy	17
Author index	17
Assessment of the impact of SARS-CoV-2 PCR results amongst thoracic oncology patients	17
Impact of risk-based low dose CT screening on different socio-economic groups	17
Magnetic resonance imaging for prospective assessment of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy	17
Contents	17
Surgical decompression of malignant spinal cord compression (MSCC) in lung cancer: the Manchester experience	17
ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype	17
Real-world outcomes with nivolumab for pre-treated malignant mesothelioma in the UK	16
Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung c	16
An integrated physiotherapy service for patients undergoing treatment for advanced thoracic cancers: an evaluation focusing on the patients’ perspectives	16
An invisible group of COVID-19 victims; impact on Dutch lung cancer care	16
Molecular testing in non-small cell lung cancer	16
Integrated oncology and geriatrics care and outcomes in patients with lung cancer: results from Wythenshawe Hospital in Manchester, a tertiary referral centre	16
Thymoma: a single centre, 10-year retrospective review	16
Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?	16
A real-world description of pathogenic mutations and their genomic context in patients with lung adenocarcinoma in East London	16
Bone protection and Pneumocystis jirovecii prophylaxis in thoracic oncology patients receiving systemic steroids for immunotherapy-related toxicity	16
Change in muscle mass and attenuation in patients receiving systemic anti-cancer therapy for advanced non-small cell lung cancer	16
Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results	15
Does lung cancer screening information support informed decision-making? A systematic environmental scan review	15
Sarcopenia is not a useful prognostic biomarker in metastatic NSCLC patients treated with first-line pembrolizumab	15
Programmed death-ligand (PD-L1) expression and tissue heterogeneity in advanced non-small cell lung cancer (NSCLC)	15
Role of lung function in predicting risk of iatrogenic pneumothorax post CT-guided lung biopsy	15
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score	15
PDL-1 assessment – how does it affect lung cancer management? A service evaluation	15
Is MRI the superior test for investigating thymic pathologies in comparison to CT?	15
Toxicity rates of accelerated concurrent chemoradiation for NSCLC and access to durvalumab at a UK cancer centre	15
Review of the work-up for patients diagnosed with malignant pleural mesothelioma in Northern Ireland 2019–2020	15
Patient survey to identify the outcome of the information given regarding lung cancer diagnosis and treatment	15
Retrospective study to compare the dosimetric difference on treatment volume (PTV) and lung V20 in patients receiving lung stereotactic ablative radiotherapy (SABR) based on use of abdominal compressi	14
Stereotactic ablative radiotherapy (SABR) for primary lung malignancy: a regional analysis of survival and recurrence outcomes amongst an elderly cohort	14
Analysis of investigation and management of patients with mesothelioma in the Mid Yorkshire Hospitals NHS Trust: a 5-year retrospective study	14
Markers of efficacy in patients treated with immunotherapy for non-small cell lung cancer: a single cancer centre experience	14
Real world outcomes in patients with lung oligometastases treated with SABR – a single-centre experience	14
Lung cancer patients over 70 years on systemic anti-cancer therapy: experience within a local centre	14
Radical radiotherapy in stage III NSCLC – why not chemoradiotherapy?	14
Contents	14
Clinico-pathological features of MET exon 14 mutation positive NSCLC in the UK	14
How do we improve concurrent chemoradiotherapy rates in stage 3 NSCLC?	14
Outcomes of surveillance imaging for non-small cell lung cancer patients treated with curative-intent: a single-centre retrospective longitudinal study	14
Clinical frailty scoring in lung cancer patients referred for palliative radiotherapy	14
Best practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions	14
Understanding patient experience: findings for Ireland and the UK and from the first Global Lung Cancer Coalition Patient Experience Survey	14

Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry	13
A reply to “Importance of designing sample size, subgroup analysis, and covariate presentation: Towards a better randomized controlled trial”	13
A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion	13
Contents	13
Editorial Board	13
Uncertain resection margins and patterns of recurrence following the surgical resection of non-small cell lung cancer	13
Clinical relevance of circulating activin A and follistatin in small cell lung cancer	13
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy	13
Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program	13
Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study	13
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation	13
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial	13
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed	13
MET inhibitors for MET amplification—What’s the most appropriate detection method and cut-off value?	13
Contents	12
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis	12
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours	12
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting f	12
Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer	12
ctDNA analysis identifies clinically meaningful resistance mutations in EGFR mutated NSCLC on osimertinib: a case report	12
COVID-19 vaccination associated lung mass mimicking a primary lung cancer: a novel manifestation	12
Editorial Board	12
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study	12
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions	12
Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?	12
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer	12
Lung resection with underlying UIP: Russian roulette	12
90-Day mortality following lung cancer surgery: contemporary outcomes from the English National Clinical Outcomes Audit	12
Contents	12
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study	12
Impact on quality of life from multi-modality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multi-modality treatment in potentially resec	12
Contents	12
Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis	12
The value of prognostic and predictive parameters in early-stage lung adenocarcinomas: A comparison between biopsies and resections	12
Comparison of a ‘real-world’ inpatient talc slurry pleurodesis service with randomised controlled trial outcomes and suggested RAG rating criteria for quality assurance	12
The first historical description of malignant mesotheliomas	12
Drive the oncologists into exercise promotion in lung cancer	11
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era	11
Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients	11
The reporting of pulmonary nodule results by letter in a lung cancer screening setting	11
Barriers and facilitators to uptake of lung cancer screening: A mixed methods systematic review	11
Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: Exploration of efficacy of unselected treatment in a multicenter cohort study	11
Stepwise progression of invasive mucinous adenocarcinoma based on radiological and biological characteristics	11
Rapid intraoperative Ki-67 immunohistochemistry for lung cancer using non-contact alternating current electric field mixing	11
Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer	11
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer	11
Clinical utility of comprehensive genomic profiling in non-small cell lung cancer: An analysis of a nation-wide database	11
Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC	11
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer	11
Thoracic NUT carcinoma: Common pathological features despite diversity of clinical presentations	11
Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902)	11
Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment	11
Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study	10
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis	10
Association of alcohol with lung cancer risk in men with different growth hormone receptor genotypes	10
1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience	10
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS	10
Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial	10
First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer	10
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS	10
Frozen sections accurately predict the IASLC proposed grading system and prognosis in patients with invasive lung adenocarcinomas	10
Race & sex disparities related to low-dose computed tomography lung cancer screening eligibility criteria: A lung cancer cases review	10
Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition	10
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer	10
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the	10
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study	10
Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer	10
The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study	10
CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis	10
Evaluating tumour budding could improve the new grading system for lung adenocarcinoma	10
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma	10
Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer	10
Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance	10
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer	10
Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study	10
Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism	9
Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors	9
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)	9
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial	9
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations	9
Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers	9
Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer	9
Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study	9
Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution	9
MTAP as an emerging biomarker in thoracic malignancies	9
Explaining differences in the frequency of lung cancer detection between the National Lung Screening Trial and community-based screening in Manchester, UK	9
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study	9
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010	9
Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT)	9
The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea	9
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients	9
A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma	9
Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon	9
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC	9
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC	9